Intralesional triamcinolone acetonide injection for chalazion
Jasna Pavicić-Astalos1, Renata Iveković, Tamara Knezević
1University Department of Ophthalmology, Sestre milosrdnice University Hospital, Zagreb, Croatia.
Acta Clinica Croatica
|July 20, 2010
Summary
Intralesional triamcinolone acetonide injections effectively treat primary and recurrent chalazion. This steroid injection offers a simple and successful therapeutic option, leading to lesion resolution in most cases.
Area of Science:
- Ophthalmology
- Dermatology
- Pharmacology
Background:
- Chalazion is a common eyelid inflammation.
- Recurrent chalazion can be challenging to treat.
- Current treatments may have limitations.
Purpose of the Study:
- To evaluate the efficacy of intralesional triamcinolone acetonide.
- To assess treatment outcomes for primary and recurrent chalazion.
- To compare triamcinolone acetonide with a saline control.
Main Methods:
- 30 patients with chalazion received triamcinolone acetonide injections.
- A control group received saline injections.
- Lesion size, regression, and recurrence were monitored.
Main Results:
- 35 out of 37 chalazion cases resolved after one or two injections.
- Mean resolution time was 15.27 days.
- Success defined as ≥80% size reduction with no recurrence.
Conclusions:
- Intralesional triamcinolone acetonide is an effective treatment for chalazion.
- It provides a simple and safe therapeutic option.
- This method shows promise for managing primary and recurrent chalazion.
